Formulation and Evaluation of Efavirenz Tablet using Moringa oleifera as a Natural Polymer
This study describes a systemic approach for the formulation and evaluation of Efavirenz tablets and has been done in this work using Moringa Oleifera as a natural polymer at different concentrations. In order to identify the medication, melting point, solubility, and FTIR analysis were used. DSC was used for investigating the drug polymer interactions. Consequently, no interaction between the medicine and polymer used in the formulation was detected. The formulations were created by blending medication and excipients, then analysing them for Angle of repose, Bulk density, Tapered bulk density, Hausner's ratio, and Carr's compressibility index. The powder blends passed all of these tests with flying colours. Direct compression was used to make the seven batches of Efavirenz pills. Thickness, hardness, friability, weight variation, and drug content were all measured on the manufactured tablets. All of the values were found to be within the parameters. All seven batches were subjected to in-vitro dissolving tests. Because Formulation F7 has the largest percentage of medication release, it has been chosen as the best formulation. Stability tests were performed on the optimised formulation F7, and the findings showed no significant changes throughout the course of the three-month investigation.
2. American Cancer Society. 2009. Possible Risks of Blood Product Transfusions; 1/13.
3. Institute of Medicine, 1986. National Academy of Sciences. Confronting
4. Barghese, B. Reducing Risk of Sexual HIV Transmission. Sexually Transmitted Diseases. 2002; 29(1):39-40.
5. Francis, D.P., The prevention of acquired immunodeficiency syndrome in the United States. JAMA; 1987; 257:1360.
6. Fuglie LJ (1999) The Miracle Tree: Moringa oleifera: Natural Nutrition
for the Tropics. Church World Service, Dakar. 68 pp; revised in 2001 and published as The Miracle Tree: The Multiple Attributes of Moringa, 172 pp.
7. Price ML (1985) The Moringa Tree. ECHO Technical Note. Educational Concerns for Hunger Organization, N. Ft. Meyers, FL. http://www.echotech.org/technical/technotes/mo ringabiomasa.pdf.
8. Matsunaga H, Eguchi T, Nishijima K, Enomoto T, Sasaoki K, Nakamura N. Solid state characterization of candesartan cilexetil (TCV-116): Crystal structure and molecular mobility. Chem Pharm Bull 1999; 47:182-6.
9. Naveen C, Shastri N, Tadikonda RR. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm Sin B 2012; 2:502-8.
10. Sanjeev Raghavendra Gubbi, Ravindra Jarag. Formulation and characterization of atorvastatin calcium liquisolid compacts. Asian J Pharm Sci 2010; 5:50-60.
11. Neelam Sreedhar, Sonu Bhatia. Solubility enhancement of cox-2 inhibitors using various solvent systems. AAPS PharmSciTech 2003; 4:E33.
12. Nokhodchi A. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J Pharm Sci 2010; 12:18-25
13. Spireas S, Bolton M. Liquisolid systems and methods of preparing same. U. S. Patent; 1999. p. 968, 550.
14. Tiong N, Elkordy AA. Effects of liquisolid formulations on the dissolution of naproxen. Eur J Pharm Biopharm 2009; 73:373-84
15. Sharma D. Solubility enhancement-eminent role in poorly soluble drugs. Res J Pharm Technol 2009; 2:220-4.
16. Vijay kumar Nagabandi, Ramarao Tadikonda, Jayaveera KN. Formulation development and evaluation of liquisolid system to improve the dissolution rate of Ketoprofen. Int J Biomed Res 2011; 2:530-41.
17. Vijay N, Ramarao T, Jaya Veera K. Liquisolid compacts a novel approach to enhance bioavailability of poorly soluble drugs. Int J Pharm Biol Sci 2011; 1:89-102.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.